-
1
-
-
84922668738
-
Targeting the TGFβ pathway for cancer therapy
-
PMID:25444759
-
Neuzillet C, Tijeras-Raballand A, Cohen R, Cros J, Faivre S, Raymond E, de Gramont A. Targeting the TGFβ pathway for cancer therapy. Pharmacol Ther 2015; 147:22-31; PMID:25444759; http://dx.doi.org/10.1016/j.pharmthera.2014.11.001
-
(2015)
Pharmacol Ther
, vol.147
, pp. 22-31
-
-
Neuzillet, C.1
Tijeras-Raballand, A.2
Cohen, R.3
Cros, J.4
Faivre, S.5
Raymond, E.6
De Gramont, A.7
-
2
-
-
84866742560
-
TGFβ signalling in context
-
PMID:22992590
-
Massagué J. TGFβ signalling in context. Nat Rev Mol Cell Biol 2012; 13:616-30; PMID:22992590; http://dx.doi.org/10.1038/nrm3434
-
(2012)
Nat Rev Mol Cell Biol
, vol.13
, pp. 616-630
-
-
Massagué, J.1
-
3
-
-
84899071195
-
Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/ pharmacodynamic model
-
PMID:24843434
-
Gueorguieva I, Cleverly AL, Stauber A, Sada Pillay N, Rodon JA, Miles CP, Yingling JM, Lahn MM. Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/ pharmacodynamic model. Br J Clin Pharmacol 2014; 77:796-807; PMID:24843434; http://dx.doi.org/10.1111/bcp.12256
-
(2014)
Br J Clin Pharmacol
, vol.77
, pp. 796-807
-
-
Gueorguieva, I.1
Cleverly, A.L.2
Stauber, A.3
Sada Pillay, N.4
Rodon, J.A.5
Miles, C.P.6
Yingling, J.M.7
Lahn, M.M.8
-
4
-
-
85009903727
-
A phase II, double-blind study of galunisertibCgemcitabine (GG) vs gemcitabineCplacebo (GP) in patients (pts) with unresectable pancreatic cancer (PC)
-
abstr 4019
-
Melisi D, Garcia-Carbonero R, Macarulla T, Pezet D, Deplanque G, Fuchs M, Trojan J, Oettle H, Kozloff M, Cleverly A et al. A phase II, double-blind study of galunisertibCgemcitabine (GG) vs gemcitabineCplacebo (GP) in patients (pts) with unresectable pancreatic cancer (PC). J Clin Oncol 2016; 34, (suppl; abstr 4019).
-
(2016)
J Clin Oncol
, vol.34 suppl
-
-
Melisi, D.1
Garcia-Carbonero, R.2
Macarulla, T.3
Pezet, D.4
Deplanque, G.5
Fuchs, M.6
Trojan, J.7
Oettle, H.8
Kozloff, M.9
Cleverly, A.10
-
5
-
-
84904426489
-
A phase 2 study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC)
-
abstr LBA173)
-
Faivre S, Santoro A, Kelley RK, Merle P, Gane E, Douillard J-Y, Waldschmidt D, Mulcahy MF, Costentin C, Minguez B et al. A phase 2 study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2014; 32, (suppl 3; abstr LBA173).
-
(2014)
J Clin Oncol
, vol.32 suppl 3
-
-
Faivre, S.1
Santoro, A.2
Kelley, R.K.3
Merle, P.4
Gane, E.5
Douillard, J.-Y.6
Waldschmidt, D.7
Mulcahy, M.F.8
Costentin, C.9
Minguez, B.10
-
6
-
-
84937067787
-
Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040
-
abstr LBA101
-
El-Khoueiry AB, Melero I, Crocenzi TS, Welling TH, Cheung Yau T, Yeo W, Chopra A, Grosso J, Lang L, Anderson J et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol 2015; 33, (suppl; abstr LBA101).
-
(2015)
J Clin Oncol
, vol.33
-
-
El-Khoueiry, A.B.1
Melero, I.2
Crocenzi, T.S.3
Welling, T.H.4
Cheung Yau, T.5
Yeo, W.6
Chopra, A.7
Grosso, J.8
Lang, L.9
Erson, J.10
-
7
-
-
84943665476
-
A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer
-
Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juhász E, Ramlau R, van den Heuvel MM, Lal R, Kloecker GH, Eaton KD et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer Oxf Engl 1990 2015; 51:2321-9.
-
(2015)
Eur J Cancer Oxf Engl
, vol.1990
, Issue.51
, pp. 2321-2329
-
-
Giaccone, G.1
Bazhenova, L.A.2
Nemunaitis, J.3
Tan, M.4
Juhász, E.5
Ramlau, R.6
van den Heuvel, M.M.7
Lal, R.8
Kloecker, G.H.9
Eaton, K.D.10
-
8
-
-
84930177428
-
Pilot trial of FANG immunotherapy in Ewing’s sarcoma
-
PMID:25917459
-
Ghisoli M, Barve M, Schneider R, Mennel R, Lenarsky C, Wallraven G, Pappen BO, LaNoue J, Kumar P, Nemunaitis D et al. Pilot trial of FANG immunotherapy in Ewing’s sarcoma. Mol Ther J Am Soc Gene Ther 2015; 23:1103-9; PMID:25917459; http://dx.doi.org/10.1038/mt.2015.43
-
(2015)
Mol Ther J am Soc Gene Ther
, vol.23
, pp. 1103-1109
-
-
Ghisoli, M.1
Barve, M.2
Schneider, R.3
Mennel, R.4
Lenarsky, C.5
Wallraven, G.6
Pappen, B.O.7
Lanoue, J.8
Kumar, P.9
Nemunaitis, D.10
-
9
-
-
79951602633
-
Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: Results of a randomized and controlled phase IIb study
-
PMID:20980335
-
Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A, Balasubramaniam A, Nair S, Oliushine V, Parfenov V et al. Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro-Oncol 2011; 13:132-42; PMID:20980335; http://dx. doi.org/10.1093/neuonc/noq142
-
(2011)
Neuro-Oncol
, vol.13
, pp. 132-142
-
-
Bogdahn, U.1
Hau, P.2
Stockhammer, G.3
Venkataramana, N.K.4
Mahapatra, A.K.5
Suri, A.6
Balasubramaniam, A.7
Nair, S.8
Oliushine, V.9
Parfenov, V.10
-
10
-
-
85034600692
-
OT-101: An anti-TGF-beta-2 antisense-primed tumors to subsequent chemotherapies
-
abstr e15727
-
Hwang L, Ng K, Wang W, Trieu VN. OT-101: An anti-TGF-beta-2 antisense-primed tumors to subsequent chemotherapies. J Clin Oncol 2016; 34, (suppl; abstr e15727).
-
(2016)
J Clin Oncol
, vol.34
-
-
Hwang, L.1
Ng, K.2
Wang, W.3
Trieu, V.N.4
-
11
-
-
84939789948
-
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
-
PMID:25529192
-
Rodón J, Carducci M, Sepulveda-Sánchez JM, Azaro A, Calvo E, Seoane J, Braña I, Sicart E, Gueorguieva I, Cleverly A et al. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Invest New Drugs 2015; 33:357-70; PMID:25529192; http://dx.doi.org/10.1007/s10637-014-0192-4
-
(2015)
Invest New Drugs
, vol.33
, pp. 357-370
-
-
Rodón, J.1
Carducci, M.2
Sepulveda-Sánchez, J.M.3
Azaro, A.4
Calvo, E.5
Seoane, J.6
Braña, I.7
Sicart, E.8
Gueorguieva, I.9
Cleverly, A.10
-
12
-
-
85009885916
-
A phase 2 study of galunisertib, a novel transforming growth factor-beta (TGF-β) receptor I kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP)
-
abstr 4070
-
Faivre S, Santoro A, Gane E, Kelley RK, Ollivier-Hourmand I, Gueorguieva I, Cleverly A, Desaiah D, Lahn MM, Raymond E et al. A phase 2 study of galunisertib, a novel transforming growth factor-beta (TGF-β) receptor I kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP). J Clin Oncol 2016; 34, (suppl; abstr 4070)
-
(2016)
J Clin Oncol
, vol.34
-
-
Faivre, S.1
Santoro, A.2
Gane, E.3
Kelley, R.K.4
Ollivier-Hourmand, I.5
Gueorguieva, I.6
Cleverly, A.7
Desaiah, D.8
Lahn, M.M.9
Raymond, E.10
|